The content on this site is intended for healthcare professionals only
Dr Trine Jakobi Nøttrup speaks to ecancer about the randomised phase II DOVACC trial.
This trial investigated whether adding the hTERT-targeting therapeutic cancer vaccine UV1 to olaparib, with or without durvalumab, could improve outcomes in patients with BRCA wild type recurrent ovarian cancer.
Median progression-free survival was 8.7 months with UV1, durvalumab and olaparib versus 5.9 months with olaparib alone.
However, the difference did not reach statistical significance.
She says that this exploratory analyses suggested potential benefit in homologous recombination deficiency-negative and PARP inhibitor-naïve subgroups, warranting further investigation.
Biomarker guided PARP inhibitor maintenance improves outcomes in ovarian cancer meta analysis of phase 3 trials
Extended interval tarlatamab dosing shows consistent clinical activity in previously treated SCLC
Therapeutic mammoplasty: An advanced oncoplastic breast surgery technique
Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC
Screen-detectable cancers account for majority of early-onset cancer cases under age 50
Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer
Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer
Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC
Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer
